Apyx Medical Q4 GAAP EPS $(0.28) May Not Be Comparable To $(0.18) Estimate, Sales $14.66M Miss $14.85M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apyx Medical (NASDAQ:APYX) reported Q4 GAAP EPS of $(0.28), missing the $(0.18) estimate by 55.56%, and a 64.71% decrease from last year's $(0.17) per share. Sales were $14.66M, missing the $14.85M estimate by 1.27%, but represent a 16.26% increase from last year's $12.61M.
March 21, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apyx Medical reported a significant miss in Q4 GAAP EPS and slight miss in sales, but showed a year-over-year sales increase.
The significant miss in EPS and slight miss in sales forecasts are likely to negatively impact investor sentiment in the short term, despite the year-over-year sales growth. The EPS miss, in particular, being significantly below analyst expectations, suggests potential underlying issues that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100